Physician profile
Lawrence Michael Arkin
NPI 1538263710
$1,386.79
in general payments reported to CMS, 2019-2025
14 companies · $58.29 in 2025
The $58.29 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $212 · 2021: $143 · 2022: $204 · 2023: $105 · 2024: $300 · 2025: $58.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.64 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $177.74 | 2024 | Xdemvy |
| Allergan, INC. | $167.24 | 2019-2021 | |
| Alcon Vision LLC | $155.32 | 2019-2025 | Rocklatan |
| Ocular Therapeutix, INC. | $154.32 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.78 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $87.34 | 2019-2021 | |
| Omeros Corporation | $58.01 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $44.01 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Biotissue Holdings INC. | $32.51 | 2020-2022 | |
| Dompe US, INC. | $25.30 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $24.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Arkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.